Before revision: Inequity of access When considering the merits of listing a medicine on the PBS, the PBAC evaluate extensive information, however there is no requirement to consider equity of access for Australians nor the impact on human rights by decisions to list or reject a pharmaceutical a change to an existing listing.. The Pharmaceutical Benefits Advisory Committee claims it cannot review medicines to add indications without a submission (pharmaceutical supplier in Australia) requesting an evaluation to change a listing.
After revision: The Pharmaceutical Benefits Advisory Committee claims it cannot review medicines to add indications without a submission (pharmaceutical supplier in Australia) requesting an evaluation to change a listing.